Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Envoy Medical (COCH) Net Income towards Common Stockholders (2022 - 2025)

Envoy Medical's Net Income towards Common Stockholders history spans 4 years, with the latest figure at -$7.4 million for Q3 2025.

  • For Q3 2025, Net Income towards Common Stockholders fell 1.42% year-over-year to -$7.4 million; the TTM value through Sep 2025 reached -$26.2 million, up 1.51%, while the annual FY2024 figure was -$20.1 million, 35.87% up from the prior year.
  • Net Income towards Common Stockholders for Q3 2025 was -$7.4 million at Envoy Medical, down from -$6.9 million in the prior quarter.
  • Across five years, Net Income towards Common Stockholders topped out at $13.1 million in Q2 2023 and bottomed at -$13.3 million in Q1 2023.
  • The 4-year median for Net Income towards Common Stockholders is -$6.9 million (2022), against an average of -$4.5 million.
  • The largest annual shift saw Net Income towards Common Stockholders skyrocketed 290.96% in 2023 before it plummeted 624.29% in 2024.
  • A 4-year view of Net Income towards Common Stockholders shows it stood at -$11.5 million in 2022, then soared by 45.34% to -$6.3 million in 2023, then increased by 21.36% to -$4.9 million in 2024, then tumbled by 50.9% to -$7.4 million in 2025.
  • Per Business Quant, the three most recent readings for COCH's Net Income towards Common Stockholders are -$7.4 million (Q3 2025), -$6.9 million (Q2 2025), and -$6.8 million (Q1 2025).